In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report), with a price target of $43.00. The company’s shares closed last Tuesday at $11.62, close to its 52-week low of $9.76.
According to TipRanks.com, Yang is a 1-star analyst with an average return of -1.2% and a 39.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.
Based on Avrobio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $36.78 million. In comparison, last year the company had a GAAP net loss of $17.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.